Compare Eli Lilly And Co (LLY) vs NetApp Inc. (NTAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs NetApp Inc. — how do they compare? Eli Lilly And Co trades at $1,208.39 (market cap $1.08T), while NetApp Inc. trades at $200.86 (market cap $38.95B). The key difference: Eli Lilly And Co is far larger — about 27.7× NetApp Inc.'s market cap, and NetApp Inc. pays the higher dividend (1.05%). Which is the better fit depends on your goals.
| LLY | NTAP | |
|---|---|---|
Market Cap | $1.08T | $38.95B |
Sector | Health | Technology |
52-Week High | $1.24K | $198.72 |
52-Week Low | $639.43 | $94.11 |
Enterprise Value | $1.13T | $38.10B |
Dividend Yield | 0.57% | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.
Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.
NetApp (NTAP) trades at $198.72, up 4.85% today, near its consensus price target high of $200. The stock shows strong technical momentum with bullish moving averages and recent earnings beats. Revenue grew to $6.57B in 2025 with an 18.43% net margin, while acquisitions like JetStream Software and DataPelago enhance its AI infrastructure capabilities. Cash flow turned positive at $840M in 2025 after two years of negative net flows.
Outlook is positive given earnings consistency and strategic AI investments, but high valuation ratios (P/E 31.26) and overbought RSI levels near 85 pose near-term risks. Analyst consensus leans Hold (50.7%), suggesting cautious optimism amid growth execution and competitive pressures in data storage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →
